ICS/LABA/LAMA疗法引起的苦味变化最为显著。吸入前不用水冲洗与苦味变化有关。含有LAMA的吸入器使用者的苦味变化与依从性差有关,这突出表明需要采取有针对性的干预措施来提高依从性。 简介 吸入疗法仍然是支气管哮喘和慢性阻塞性肺病(...
Objective To investigate the effects of first-time use of single-inhaler therapy with long-acting beta-2 agonist/long-acting antimuscarinic agent (LABA/LAMA) and inhaled corticosteroids (ICS)/LABA on adherence and exacerbations in patients with chronic obstructive pu...
The results are promising and favor the LAMA/LABA inhalers, especially in the longer duration trials. Furthermore, there is a clearer picture emerging as to the subgroup of COPD patients who may be able to successfully switch from their current ICS/LABA therapy to these new LAMA/LABA inhaler...
However, it is still unclear whether LABA or LAMA should be used for the initial treatment. Therefore, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of LABA versus LAMA in patients with stable COPD. Methods We searched relevant randomized control trials (...
LABA (salmeterol) significantly improved asthma control when added to ICS compared with placebo (measured by Asthma Control Questionnaire [ACQ])21. The LTRA (montelukast) did not have an effect on asthma control when compared with placebo (measured by ACQ) (Table2)32. Data for LAMA (tiotropium...
The search terms were "COPD" AND inhaled drugs ("LAMA" AND "LABA") AND randomized controlled design, which included controlled vocabulary and free text. The LAMAs included aclidinium, glycopyrrolate, tiotropium with a dry powder inhaler or soft mist inhaler, and ume- clidinium. The LABAs ...
It is unclear whether adding a LAMA to ICS/LABA therapy has an impact on adherence to treatment, despite the good safety profile. When adding a LAMA to maintenance therapy, it is likely that combining the multiple drugs in one single inhaler device could enhance adherence, but little real-wor...
10 LAMA/LABA FDCs also improve both transitional dyspnea index and St. George’s Respiratory Questionnaire scores. Furthermore, there is also clear evidence that when the goal of the therapy is to enhance exercise capacity in patients with COPD, LAMA/LABA FDCs consistently meet the putative ...
And Then There Were Three: Time to Move Onward in COPD Drug Development Beyond LAMA/LABA/ICS at Last?doi:10.1007/s41030-018-0059-5COPDIMPACTInhaled corticosteroidsInhaler combinationsLAMA/LABA/ICSTRIBUTEKai M. BeehInsaf Respiratory Research InstitutePulmonary Therapy...
Schroeder M, Benjamin N, Atienza L, et al. Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a Spanish perspective.Int J Chron Obstruct Pulmon Dis. 2020;15:1621–1632. ...